215 related articles for article (PubMed ID: 34716208)
1. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy.
Kortekaas KE; Santegoets SJ; Tas L; Ehsan I; Charoentong P; van Doorn HC; van Poelgeest MIE; Mustafa DAM; van der Burg SH
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34716208
[TBL] [Abstract][Full Text] [Related]
2. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
[TBL] [Abstract][Full Text] [Related]
3. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
Xing D; Fadare O
Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
[TBL] [Abstract][Full Text] [Related]
4. An integrated model for prognosis in vulvar squamous cell carcinoma.
Zhang T; Zhu Y; Luo J; Li J; Niu S; Chen H; Zhou F
BMC Cancer; 2023 Jun; 23(1):534. PubMed ID: 37308869
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in HPV-associated Versus HPV-independent Invasive Vulvar Squamous Cell Carcinoma.
Bui CM; Medeiros F; Azimpouran M; Venturina M; Balzer B
Int J Gynecol Pathol; 2024 Jul; 43(4):405-413. PubMed ID: 38303111
[TBL] [Abstract][Full Text] [Related]
6. The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy.
Abdulrahman Z; Kortekaas KE; De Vos Van Steenwijk PJ; Van Der Burg SH; Van Poelgeest MI
Expert Opin Biol Ther; 2018 Dec; 18(12):1223-1233. PubMed ID: 30373410
[TBL] [Abstract][Full Text] [Related]
7. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
Cocks M; Chaux A; Jenson EG; Miller JA; Rodriguez Pena MDC; Tregnago AC; Taheri D; Eich ML; Sharma R; Vang R; Netto GJ
Virchows Arch; 2020 Jul; 477(1):93-102. PubMed ID: 31993774
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
Chinn Z; Stoler MH; Mills AM
Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
[TBL] [Abstract][Full Text] [Related]
10. Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination.
Abdulrahman Z; de Miranda N; van Esch EMG; de Vos van Steenwijk PJ; Nijman HW; J P Welters M; van Poelgeest MIE; van der Burg SH
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169871
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
Sznurkowski JJ; Żawrocki A; Sznurkowska K; Pęksa R; Biernat W
Oncotarget; 2017 Oct; 8(52):89903-89912. PubMed ID: 29163797
[TBL] [Abstract][Full Text] [Related]
12. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
[TBL] [Abstract][Full Text] [Related]
13. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Choschzick M; Gut A; Fink D
Virchows Arch; 2018 Oct; 473(4):513-516. PubMed ID: 29736798
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.
Wang Z; Førsund MS; Trope CG; Nesland JM; Holm R; Slipicevic A
Cancer Med; 2018 Aug; 7(8):3955-3964. PubMed ID: 29963769
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes.
Kortekaas KE; Bastiaannet E; van Doorn HC; de Vos van Steenwijk PJ; Ewing-Graham PC; Creutzberg CL; Akdeniz K; Nooij LS; van der Burg SH; Bosse T; van Poelgeest MIE
Gynecol Oncol; 2020 Dec; 159(3):649-656. PubMed ID: 32972785
[TBL] [Abstract][Full Text] [Related]
18. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
19. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
20. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.
Clancy AA; Spaans JN; Weberpals JI
Ann Oncol; 2016 Sep; 27(9):1696-705. PubMed ID: 27329249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
